Sight Care vs GLP-1 Medications: Honest Comparison
Sight Care is a vision support and eye health supplement — but can it actually replace GLP-1 medications like Ozempic, Wegovy, and Mounjaro? Below we examines how they stack up so you can make an informed decision.
The Science Behind Each
Sight Care
- Mechanism: Protecting retinal cells and supporting healthy vision through antioxidant compounds
- Type: Over-the-counter supplement
- Active ingredients: Niacin, N-Acetyl Cysteine, and others
- Evidence level: Early-stage — no published RCTs on the formula
GLP-1 Medications (Ozempic, Wegovy, Mounjaro)
- Mechanism: Binding to GLP-1 (or dual GIP/GLP-1) receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity
- Type: Regulated prescription treatments
- Evidence level: Extensive — thousands of patients in Phase III RCTs
Effectiveness
| Factor | Sight Care | GLP-1 Medications |
|---|---|---|
| Expected weight loss | Unproven | 25-52 lbs over 68 weeks |
| Clinical evidence | Weak | Extensive RCTs |
| FDA status | Not evaluated | Regulated drug |
| Side effects | Poorly characterized | Characterized in trials |
| Cost | $69/bottle/month | $850-$1,500/month |
| Access | OTC, no prescription | Prescription required |
When Sight Care Might Make Sense
Sight Care should never be considered a equivalent for prescription drugs. However, certain cases where it could have a place:
- After stopping GLP-1s — For maintenance support during the period after medication
- When prescriptions aren’t available — When pharmaceutical options aren’t feasible
- As a complement — Supplementing a comprehensive health plan
Our Assessment
It would be irresponsible to claim that Sight Care is equivalent to GLP-1 medications. The gulf between supplement claims and drug data is massive. For patients requiring clinically significant weight loss results, FDA-approved drugs are far better supported. Sight Care could provide marginal support but cannot replace medical treatment evidence-based medicine.